Brean sees big upside for Endocyte on vintafolide potential

|By:, SA News Editor

Brean starts Endocyte (ECYT) — which rose 7% Friday — at Buy.

Analyst Gene Mack's $21 target is derived by discounting potential revenue from the Merck-partnered (MRK), folate receptor-targeting cancer treatment vintafolide.

Mack sees peak worldwide sales of $2B in 2026 and notes that potential sales of vintafolide and its companion diagnostic etarfolatide in ovarian cancer alone add $6 to the discounted revenue model.